Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study

Leukemia Research

Volumn 61, Issue , 2017, Pages 10-17

  Frairia, Chiara ^a   Aydin, Semra ^a   Audisio, Ernesta ^a   Riera, Ludovica ^a   Aliberti, Sabrina ^a   Allione, Bernardino ^a   Busca, Alessandro ^a   D'Ardia, Stefano ^a   Dellacasa, Chiara Maria ^a   Demurtas, Anna ^a   Evangelista, Andrea ^a   Ciccone, Giovannino ^a   Francia di Celle, Paola ^a   Nicolino, Barbara ^a   Stacchini, Alessandra ^a   Marmont, Filippo ^a   Vitolo, Umberto ^a  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Induction treatment; Minimal residual disease; WT1 overexpression

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER; WT1 PROTEIN; WT1 PROTEIN, HUMAN;

ADULT; AGED; BIOSYNTHESIS; DISEASE FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MORTALITY; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; WT1 PROTEINS; YOUNG ADULT;

EID: 85028355102     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2017.08.008     Document Type: Article

References (30)

1. Goldman, J.M., Gale, R.P., What does MRD in leukemia really mean?. Leukemia, 28(5), 2014, 1131.
2. Grimwade, D., Vyas, P., Freeman, S., Assessment of minimal residual disease in acute myeloid leukemia. Curr. Opin. Oncol. 22:6 (2010), 656–663.
3. Buccisano, F., Maurillo, L., Del Principe, M.I., et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 119:2 (2012), 332–341.
4. van der Velden, V.H., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J., van Dongen, J.J., Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17:6 (2003), 1013–1034.
5. Corbacioglu, A., Scholl, C., Schlenk, R.F., et al. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J. Clin. Oncol. 28:23 (2010), 3724–3729.
6. Gorello, P., Cazzaniga, G., Alberti, F., et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 20:6 (2006), 1103–1108.
7. Steinbach, D., Schramm, A., Eggert, A., et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin. Cancer Res. 12:8 (2006), 2434–2441.
8. Cilloni, D., Gottardi, E., De Micheli, D., et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16:10 (2002), 2115–2121.
9. Cilloni, D., Renneville, A., Hermitte, F., et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J. Clin. Oncol. 27:31 (2009), 5195–5201.
10. Barragan, E., Cervera, J., Bolufer, P., et al. Prognostic implications of Wilms’ tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 89:8 (2004), 926–933.
11. Hamalainen, M.M., Kairisto, V., Juvonen, V., et al. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur. J. Haematol. 80:3 (2008), 201–207.
12. Nomdedeu, J.F., Hoyos, M., Carricondo, M., et al. Bone marrow WT1 levels at diagnosis: post-induction and post-intensification in adult de novo AML. Leukemia 27:11 (2013), 2157–2164.
13. Ostergaard, M., Olesen, L.H., Hasle, H., Kjeldsen, E., Hokland, P., WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients — results from a single-centre study. Br. J. Haematol. 125:5 (2004), 590–600.
14. Cheson, B.D., Bennett, J.M., Kopecky, K.J., et al. Revised recommendations of the international working group for diagnosis: standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J. Clin. Oncol. 21:24 (2003), 4642–4649.
15. Bassan, R., Barbui, T., Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age?. Haematologica 80:1 (1995), 82–90.
16. Dohner, H., Estey, E.H., Amadori, S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:3 (2010), 453–474.
17. Parker, J.E., Pagliuca, A., Mijovic, A., et al. Fludarabine: cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br. J. Haematol. 99:4 (1997), 939–944.
18. ®16 Instrument Article. 2013 (accessed) http://ita.promega.com/resources/pubhub/high-quality-rna-from-blood-and-bone-marrow-after-automated-extraction-on-maxwell16-instrument/.
19. van Dongen, J.J., Macintyre, E.A., Gabert, J.A., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia 13:12 (1999), 1901–1928.
20. Gooley, T.A., Leisenring, W., Crowley, J., Storer, B.E., Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat. Med. 18:6 (1999), 695–706.
21. Fine, J., Gray, R., A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94:446 (1999), 496–497.
22. Nowakowska-Kopera, A., Sacha, T., Florek, I., Zawada, M., Czekalska, S., Skotnicki, A.B., Wilms’ tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. Leuk. Lymphoma 50:8 (2009), 1326–1332.
23. Mossallam, G.I., Abdel Hamid, T.M., Mahmoud, H.K., Prognostic significance of WT1 expression at diagnosis and end of induction in Egyptian adult acute myeloid leukemia patients. Hematology 18:2 (2013), 69–73.
24. Valkova, V., Polak, J., Markova, M., et al. Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis. Clin. Transplant. 27:1 (2013), E21–E29.
25. Rossi, G., Carella, A.M., Minervini, M.M., et al. Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms’ tumor 1 expression. Leuk. Res. 39:2 (2015), 138–143.
26. Gianfaldoni, G., Mannelli, F., Ponziani, V., et al. Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematologica 95:5 (2010), 833–836.
27. Pozzi, S., Geroldi, S., Tedone, E., et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br. J. Haematol. 160:4 (2013), 503–509.
28. Candoni, A., Toffoletti, E., Gallina, R., et al. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin. Transplant. 25:2 (2011), 308–316.
29. Malagola, M., Skert, C., Ruggeri, G., et al. Peripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation. BioMed Res. Int., 2014, 2014, 123079.
30. Polak, J., Hajkova, H., Haskovec, C., et al. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia — a useful tool for early detection of minimal residual disease. Neoplasma 60:1 (2013), 74–82.